Skip to main navigation Skip to search Skip to main content

Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits

  • Yanli Wang
  • , Liang Bai
  • , Yan Lin
  • , Yulong Chen
  • , Hua Guan
  • , Ninghong Zhu
  • , Yafeng Li
  • , Shoucui Gao
  • , Lijing Sun
  • , Sihai Zhao
  • , Jianglin Fan
  • , Enqi Liu
  • Xi'an Jiaotong University
  • Xi'an Medical University
  • University of Yamanashi

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Background: Atherosclerotic cardiovascular disease is one of the major diseases that seriously impacts human health. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events. Aim: The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits. Methods and Results: Thirty Japanese white rabbits were fed with a high cholesterol diet for 12 weeks, which was supplemented with either 0.005 % atorvastatin alone or 0.005 % atorvastatin plus 0.3 % probucol and 0.3 % cilostazol. Except for high-density lipoprotein cholesterol, no difference was found in plasma lipids among vehicle, statin, and the combined treatment group. However, atherosclerotic lesions were significantly reduced by statin treatment compared with vehicle. Moreover, we found that the anti-atherogenic effect of statin was further enhanced by the combined treatment, which was due to increased anti-inflammatory and anti-oxidant properties. Conclusions: These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect.

Original languageEnglish
Article number82
JournalLipids in Health and Disease
Volume14
Issue number1
DOIs
StatePublished - 29 Jul 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Atherosclerosis
  • Atorvastatin
  • Cilostazol
  • Probucol
  • Rabbits

Fingerprint

Dive into the research topics of 'Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits'. Together they form a unique fingerprint.

Cite this